Vascepa sparkle set to light up Amarin's fourth quarter revenue

Basking in the glow of its keenly anticipated FDA approval for its fish oil pill in the blockbuster indication of reducing cardiovascular risk in patients already on statins, Amarin on Tuesday unveiled its preliminary fourth-quarter revenue that beat Wall Street estimates.